When tissue is no longer the issue

Tissue-agnostic cancer therapy comes of age

Shiuh-Wen Luoh, Keith T. Flaherty

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these vulnerabilities range from specific molecular alterations pointing to direct drug strategies to harnessing immune recognition of genetically altered epitopes produced by the cancer cells. Recent advances have found that the success of biomarker-driven cancer therapy may be relevant across sites of origin. For example, cancer types that show DNA mismatch repair deficiency, such as colon, biliary, and endometrial cancer, are more sensitive to immune checkpoint inhibition. Several large, ongoing clinical trials with a “basket” design are combining tumor tissue genomics with potential off-the-shelf therapies in drug development, and more tissue-agnostic biomarker therapies are reaching the bedside.

    Original languageEnglish (US)
    Pages (from-to)233-239
    Number of pages7
    JournalAnnals of Internal Medicine
    Volume169
    Issue number4
    DOIs
    StatePublished - Aug 21 2018

    Fingerprint

    Neoplasms
    Therapeutics
    DNA Repair-Deficiency Disorders
    Precision Medicine
    DNA Mismatch Repair
    Endometrial Neoplasms
    Tumor Biomarkers
    Genomics
    Colonic Neoplasms
    Epitopes
    Biomarkers
    Clinical Trials
    Drug Therapy
    Mutation
    Growth
    Pharmaceutical Preparations

    ASJC Scopus subject areas

    • Internal Medicine

    Cite this

    When tissue is no longer the issue : Tissue-agnostic cancer therapy comes of age. / Luoh, Shiuh-Wen; Flaherty, Keith T.

    In: Annals of Internal Medicine, Vol. 169, No. 4, 21.08.2018, p. 233-239.

    Research output: Contribution to journalArticle

    @article{f32409e2321d4eea8fc2a87b4b8aff51,
    title = "When tissue is no longer the issue: Tissue-agnostic cancer therapy comes of age",
    abstract = "Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these vulnerabilities range from specific molecular alterations pointing to direct drug strategies to harnessing immune recognition of genetically altered epitopes produced by the cancer cells. Recent advances have found that the success of biomarker-driven cancer therapy may be relevant across sites of origin. For example, cancer types that show DNA mismatch repair deficiency, such as colon, biliary, and endometrial cancer, are more sensitive to immune checkpoint inhibition. Several large, ongoing clinical trials with a “basket” design are combining tumor tissue genomics with potential off-the-shelf therapies in drug development, and more tissue-agnostic biomarker therapies are reaching the bedside.",
    author = "Shiuh-Wen Luoh and Flaherty, {Keith T.}",
    year = "2018",
    month = "8",
    day = "21",
    doi = "10.7326/M17-2832",
    language = "English (US)",
    volume = "169",
    pages = "233--239",
    journal = "Annals of Internal Medicine",
    issn = "0003-4819",
    publisher = "American College of Physicians",
    number = "4",

    }

    TY - JOUR

    T1 - When tissue is no longer the issue

    T2 - Tissue-agnostic cancer therapy comes of age

    AU - Luoh, Shiuh-Wen

    AU - Flaherty, Keith T.

    PY - 2018/8/21

    Y1 - 2018/8/21

    N2 - Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these vulnerabilities range from specific molecular alterations pointing to direct drug strategies to harnessing immune recognition of genetically altered epitopes produced by the cancer cells. Recent advances have found that the success of biomarker-driven cancer therapy may be relevant across sites of origin. For example, cancer types that show DNA mismatch repair deficiency, such as colon, biliary, and endometrial cancer, are more sensitive to immune checkpoint inhibition. Several large, ongoing clinical trials with a “basket” design are combining tumor tissue genomics with potential off-the-shelf therapies in drug development, and more tissue-agnostic biomarker therapies are reaching the bedside.

    AB - Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these vulnerabilities range from specific molecular alterations pointing to direct drug strategies to harnessing immune recognition of genetically altered epitopes produced by the cancer cells. Recent advances have found that the success of biomarker-driven cancer therapy may be relevant across sites of origin. For example, cancer types that show DNA mismatch repair deficiency, such as colon, biliary, and endometrial cancer, are more sensitive to immune checkpoint inhibition. Several large, ongoing clinical trials with a “basket” design are combining tumor tissue genomics with potential off-the-shelf therapies in drug development, and more tissue-agnostic biomarker therapies are reaching the bedside.

    UR - http://www.scopus.com/inward/record.url?scp=85051970398&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85051970398&partnerID=8YFLogxK

    U2 - 10.7326/M17-2832

    DO - 10.7326/M17-2832

    M3 - Article

    VL - 169

    SP - 233

    EP - 239

    JO - Annals of Internal Medicine

    JF - Annals of Internal Medicine

    SN - 0003-4819

    IS - 4

    ER -